LABT logo

Lakewood-Amedex Biotherapeutics, Inc.

LABT
Healthcare|Biotechnology|US
$0.39
-0.15 (-28.54%)
Tangible Book / Share
$3.05
Cash / Share
$3.23
Next Earnings Report
Nov 12, 2026
EPS est. -$1.33
Financing Filings (last 12 months)
16
Shelf registrations / offering prospectuses — latest Sep 18, 2026 (S-1). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
Nov 5, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
Oct 21, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Oct 7, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Oct 1, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Sep 28, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Sep 24, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Sep 21, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Sep 18, 2026 · PRNewsWire
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · PRNewsWire

SEC Filings (35)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 29, 20268-KMaterial eventDocumentIndex
Sep 24, 2026EFFECTDocumentIndex
Sep 18, 2026S-1IPO / offering registrationDocumentIndex
Aug 17, 2026424B3Offering prospectusDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 10, 2026DEFA14AProxy / shareholder voteDocumentIndex
Aug 10, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 30, 2026PRE 14AProxy / shareholder voteDocumentIndex
Jul 15, 20268-KMaterial eventDocumentIndex
Jun 23, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 22, 2026424B3Offering prospectusDocumentIndex
Jun 22, 2026424B3Offering prospectusDocumentIndex
Jun 17, 20268-KMaterial eventDocumentIndex
May 26, 2026424B3Offering prospectusDocumentIndex
May 26, 2026424B3Offering prospectusDocumentIndex
May 22, 202610-QQuarterly reportDocumentIndex
May 14, 2026424B4Offering prospectusDocumentIndex
May 13, 2026EFFECTDocumentIndex
May 1, 2026S-1IPO / offering registrationDocumentIndex
Apr 30, 2026424B3Offering prospectusDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Apr 23, 2026424B4Offering prospectusDocumentIndex
Apr 22, 2026CERTDocumentIndex
Apr 17, 2026EFFECTDocumentIndex
Apr 17, 20268-A12BDocumentIndex
Apr 6, 2026S-1/AIPO / offering registrationDocumentIndex
Apr 1, 2026S-1/AIPO / offering registrationDocumentIndex
Mar 11, 2026S-1/AIPO / offering registrationDocumentIndex
Feb 13, 2026S-1/AIPO / offering registrationDocumentIndex
Feb 5, 2026S-1/AIPO / offering registrationDocumentIndex
Jan 9, 2026S-1IPO / offering registrationDocumentIndex
Oct 17, 2025DRS/ADocumentIndex
Jul 31, 2025DRSDocumentIndex